JAK-IN-25
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM. JAK-IN-25 has the potential for cancer research[1].
Product Specifications
CAS Number
[2127110-22-7]
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak-in-25.html
Purity
98.44
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NN2C=C(C3=CN(CC4=CC=C(C=C4)OC)N=C3)NC(C2=C1)=O)OC
Molecular Formula
C19H17N5O4
Molecular Weight
379.37
References & Citations
[1]Matthew Frank Brown, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. US20230045252A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; Tyk2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
AHSA1 (Activator of 90kD Heat Shock Protein ATPase Homolog 1, AHA1, p38, HSPC322, C14orf3) (MaxLight 550)
AHSA1 (Activator of 90kD Heat Shock Protein ATPase Homolog 1, AHA1, p38, HSPC322, C14orf3) (MaxLight 550)